Welcome to our dedicated page for TC BioPharm (Holdings) news (Ticker: TCBP), a resource for investors and traders seeking the latest updates and insights on TC BioPharm (Holdings) stock.
TC BioPharm (Holdings) PLC (TCBP) generates a steady flow of news as a clinical-stage biopharmaceutical company developing allogeneic gamma-delta T cell therapies for cancer and other indications. News coverage on this page focuses on the company’s clinical progress, strategic initiatives, and capital markets developments, helping readers follow how its gamma-delta T cell platform is advancing from early-stage research into later-stage trials and potential new indications.
Many updates relate to TCB008, the company’s lead gamma-delta T cell therapy candidate. Articles highlight milestones in the ACHIEVE Phase II UK clinical trial, including completion of dosing in Cohort A for relapsed or refractory acute myeloid leukemia patients, initial dosing and follow-up in Cohort B minimal residual disease patients, safety findings with no reported drug-related adverse events, and efficacy signals such as stable disease and complete molecular remission in at least one MRD patient. These reports provide insight into how TCB008 is performing in challenging hematologic malignancies.
Other news items cover strategic and corporate actions, such as TC BioPharm’s intention to conduct proof-of-concept preclinical studies of TCB008 in H5N1 (avian “bird flu”), a non-binding letter of intent to acquire a commercial-stage ophthalmic pharmaceutical company with an FDA-approved glaucoma treatment, and operational changes including a shift toward a CDMO-based manufacturing model and associated workforce reductions. Capital markets announcements, including an ADS ratio change and the company’s transition from Nasdaq to trading on OTC Markets, are also reported.
Investors and observers can use this news feed to track clinical data readouts, expansion into new therapeutic areas, proposed M&A activity, and listing or ADS structure changes. For those following TCBP, revisiting this page offers a consolidated view of how the company’s gamma-delta T cell programs and broader strategy evolve over time.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
Summary not available.
TC BioPharm (NASDAQ: TCBP) has outlined its 2023 strategic plan, focusing on the development of its lead product, TCB-008, an allogeneic gamma-delta T cell therapy for cancer. The Company aims to pursue exclusive partnerships for clinical research, enhancing its competitive edge in the evolving cell therapy landscape. TCB-008 is set for FDA IND filing in Q3 2023 for Acute Myeloid Leukemia and will expand into CAR therapy targeting ovarian cancer. With over 313,000 new ovarian cancer cases reported in 2020, the Company is aligning its assets for better market positioning. TCBP is focused on establishing collaborations and increasing its intellectual property portfolio, aiming for a pivotal role in gamma-delta T cell therapies. The CEO emphasized the importance of partnerships and efficient capital management for long-term growth.